Alaunos Therapeutics Inc (TCRT)
1.32
-0.07
(-5.04%)
USD |
NASDAQ |
May 03, 14:03
Alaunos Therapeutics Cash from Financing (TTM): -18.14M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -18.14M |
September 30, 2023 | -9.664M |
June 30, 2023 | -11.77M |
March 31, 2023 | 0.209M |
December 31, 2022 | 6.367M |
September 30, 2022 | -2.293M |
June 30, 2022 | 24.74M |
March 31, 2022 | 24.76M |
December 31, 2021 | 25.78M |
September 30, 2021 | 26.36M |
June 30, 2021 | 1.463M |
March 31, 2021 | 1.456M |
December 31, 2020 | 102.12M |
September 30, 2020 | 104.75M |
June 30, 2020 | 160.61M |
March 31, 2020 | 160.83M |
December 31, 2019 | 59.15M |
September 30, 2019 | 97.47M |
June 30, 2019 | 41.58M |
March 31, 2019 | 41.04M |
December 31, 2018 | 40.31M |
September 30, 2018 | -2.063M |
June 30, 2018 | -2.062M |
March 31, 2018 | 44.54M |
December 31, 2017 | 45.30M |
Date | Value |
---|---|
September 30, 2017 | 45.84M |
June 30, 2017 | 45.84M |
March 31, 2017 | -1.124M |
December 31, 2016 | -0.788M |
September 30, 2016 | 0.759M |
June 30, 2016 | 0.852M |
March 31, 2016 | 2.086M |
December 31, 2015 | 98.34M |
September 30, 2015 | 103.82M |
June 30, 2015 | 107.44M |
March 31, 2015 | 107.22M |
December 31, 2014 | 11.44M |
September 30, 2014 | 58.52M |
June 30, 2014 | 55.02M |
March 31, 2014 | 54.67M |
December 31, 2013 | 54.54M |
September 30, 2013 | 0.457M |
June 30, 2013 | 0.279M |
March 31, 2013 | 0.381M |
December 31, 2012 | 48.98M |
September 30, 2012 | 49.31M |
June 30, 2012 | 49.45M |
March 31, 2012 | 61.58M |
December 31, 2011 | 84.31M |
September 30, 2011 | 84.19M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-18.14M
Minimum
Dec 2023
160.83M
Maximum
Mar 2020
41.88M
Average
24.76M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
NeuroBo Pharmaceuticals Inc | -0.08M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.625M |